Research Article
Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients
Table 2
Comparison of baseline characteristics across the HPR groups.
| | Variable | () | () |
| | Age group, (%) | | | | ≥60 | 23 (15.44) | 12 (8.57) | | <60 | 126 (84.56) | 128 (91.43) | | Gender, (%) | | | | Male | 117 (78.52) | 87 (62.14) | | Female | 32 (21.48) | 53 (37.86) | | BMI (kg/m2 median, min-max) | 23.04 (13.67-37.47) | 21.39 (13.34-35.34) | | Weight loss, (%) | | | | 0-5 kg | 127 (85.23) | 94 (67.14) | | 5-10 kg | 13 (8.72) | 30 (21.43) | | >10 kg | 9 (6.04) | 16 (11.43) | | Smoking history, (%) | | | | Yes | 76 (51.01) | 62 (44.29) | | No | 73 (48.99) | 78 (55.71) | | ECOG performance scale, (%) | | | | 0 | 25 (16.78) | 15 (10.71) | | 1 | 122 (81.88) | 116 (82.86) | | 2 | 2 (1.34) | 9 (6.43) | | WHO histopathologic grade, (%) | | | | 1 | 1 (0.67) | 1 (0.71) | | 2 | 7 (4.7) | 7 (5) | | 2-3 | 6 (4.03) | 3 (2.14) | | 3 | 133 (89.26) | 128 (91.43) | | Unknown | 2 (1.34) | 1 (0.71) | | Clinical stage, (%) | | | | III | 30 (20.13) | 15 (10.71) | | IVA | 78 (52.35) | 78 (55.71) | | IVB | 41 (27.52) | 47 (33.58) | | T, (%) | | | | T1-T3 | 45 (30.2) | 74 (25.61) | | T4 | 104 (69.8) | 215 (74.39) | | N, (%) | | | | N0-N1 | 40 (26.85) | 29 (20.71) | | N2-N3 | 109 (73.15) | 111 (79.29) | | Therapy, (%) | | | | CCRT | 110 (73.83) | 91 (65) | | NAC+CCRT | 35 (23.49) | 47 (33.57) | | RT | 4 (2.68) | 2 (1.43) | | RT cycle, fraction (median, min-max) | 34.46 (33-39) | 34.23 (15-39) | | Total dose (Gy (median, min-max)) | 69.69 (66-78) | 68.73 (30-78) | | Overall time (days (median, min-max)) | 54.68 (40-91) | 56.41(23-97) | | Chemosensitizer, (%) | | | | <5 cycles | 54 (36.24) | 50 (35.71) | | ≥5 cycles | 95 (63.76) | 90 (64.29) | | RT technique, (%) | | | | 2D/3DRCT | 85 (57.05) | 83 (59.29) | | 2D/3DRCT+IMRT | 8 (5.37) | 6 (4.29) | | IMRT | 56 (37.58) | 51 (36.42) | | Transfusion on CCRT, (%) | | | | Yes | 49 (32.89) | 75 (53.57) | | No | 100 (67.11) | 65 (46.43) | | Follow up duration (days (median, min-max)) | 822 (65-1095) | 760 (27-1095) |
|
|
Note: 2D: two dimensional; 3D-CRT: three-dimensional-conformal radiotherapy; BMI: body mass index; CCRT: concurrent chemoradiotherapy; ECOG: Eastern Cooperative Oncology Group; IMRT: intensity-modulated radiotherapy; NAC: neoadjuvant chemotherapy; RT: radiotherapy; WHO: World Health Organization.
|
